TJC Clarifies Prophylactic Use of Anticoagulants
The Joint Commission recently issued a series of Frequently Asked Questions (FAQs) about their revised National Patient Safety Goal, NPSG.03.05.01, which is effective July 1, 2019. NPSG.03.05.01 requires organizations to reduce the potential for patient harm associated with the use of anticoagulant therapy.
TJC has clarified that NPSG.03.05.01 does not apply to the short-term, prophylactic use of anticoagulants for venous thromboembolism prevention. For example, therapeutic doses of heparin as an infusion for DVT prophylaxis after orthopedic surgery or other short-term use related to procedures or hospitalization.
Organizations should remember that this NPSG does apply to pharmacologic venous thromboembolism (VTE) treatment.
Want to read the full alert and receive alert emails?